ASCO: AstraZeneca Touts LAURA’s Large PFS Benefit In EGFR-Mutant NSCLC

While the study allowed a crossover, and the overall survival benefit did not reach statistical significance, the drug maker sees the PFS benefit from Tagrisso as likely to drive uptake.